Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.


Latest News

12.08.2015: AH: WILEX AG announces discontinuation of collaboration between its subsidiary Heidelberg Pharma and Roche. WILEX AG was informed today that Roche is discontinuing its partnership with the WILEX subsidiary Heidelberg Pharma GmbH with respect to their collaboration in the field of antibody-targeted amanitin conjugates (ATACs). ....More




Seite gelesen: 365266 | Heute: 2179